SS Innovations International Inc. (NASDAQ: SSII) has reported that its SSi Mantra surgical robotic system has supported 195 telerobotic surgeries as of September 28, 2026, including cardiac procedures performed across significant geographic distances. The milestone matters because it moves telerobotic surgery from experimental concept toward clinical routine, with implications for how hospitals deliver specialized care to underserved regions and how investors value the emerging remote-surgery market.
The company’s installed base grew 45% to 244 systems across 12 countries, with cumulative surgical procedures reaching 14,503 and approximately 1,500 physicians trained on the platform. That scale is important because robotic surgery adoption depends on trained surgeons and proven procedure volumes; a growing installed base and physician network can create a self-reinforcing cycle that supports further adoption and recurring instrument revenue.
Recent international expansion includes new robotic cardiac surgery programs in Colombia, Sri Lanka, and India. Cardiac procedures are among the most complex in surgery, so their inclusion in the telesurgery count signals that the technology is being applied to high-acuity cases rather than only simpler operations. For patients in markets with limited access to specialist surgeons, remote procedures could reduce travel and waiting times, while hospitals could extend the reach of expert surgeons across multiple sites.
SS Innovations is also pursuing U.S. FDA clearance and European Union CE marking to support entry into additional markets. Regulatory approvals in those jurisdictions would be significant because they would open access to two of the world’s largest healthcare markets and could accelerate partnerships with hospitals and distributors. The company develops the SSi Mantra system and the SSi Mudra suite of surgical instruments, and it positions its technology as affordable and accessible; that cost focus could matter in price-sensitive markets where robotic surgery has historically been concentrated in well-funded hospitals.
For investors, the telesurgery count and installed-base growth provide concrete operating metrics in a sector where announcements often lack clinical validation. The combination of procedure volume, international expansion, and regulatory progress may help SS Innovations compete in a market increasingly shaped by communications technology and remote care. More detail is available in the full article at https://ibn.fm/S3TFq, and the company’s website at SSInnovations.com. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
The announcement was distributed through TechMediaWire, one of more than 75 brands within the Dynamic Brand Portfolio at IBN. The platform provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. Full terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
